Items where authors include "Powles, T"

Article

Brown, JE, Royle, K-L orcid.org/0000-0003-0225-1199, Gregory, W et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Hussain, SA, Lester, JF, Jackson, R et al. (17 more authors) (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. The Lancet Oncology, 23 (5). pp. 650-658. ISSN 1213-9432

van der Heijden, MS, Powles, T, Petrylak, D et al. (22 more authors) (2022) Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature Communications, 13. 1878. ISSN 2041-1723

Hall, PE, Shepherd, STC, Brown, J et al. (19 more authors) (2020) Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. European Urology Focus, 6 (5). P999-P1005. ISSN 2405-4569

Lee, LYW, Cazier, J-B, Starkey, T et al. (37 more authors) (2020) COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. The Lancet Oncology. ISSN 1470-2045

Witjes, JA, Babjuk, M, Bellmunt, J et al. (119 more authors) (2020) Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250]. European Urology, 78 (1). e48-e50. ISSN 0302-2838

Lee, LYW, Cazier, J-B, Angelis, V et al. (36 more authors) (2020) COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. The Lancet, 395 (10241). pp. 1919-1926. ISSN 0140-6736

Witjes, JA, Babjuk, M, Bellmunt, J et al. (118 more authors) (2020) EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. European Urology, 77 (2). pp. 223-250. ISSN 0302-2838

Buckley, HL orcid.org/0000-0002-9829-5817, Collinson, FJ, Ainsworth, G et al. (15 more authors) (2019) PRISM protocol: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. BMC Cancer, 19. ARTN: 1102. ISSN 1471-2407

Horwich, A, Babjuk, M, Bellmunt, J et al. (118 more authors) (2019) EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. Annals of Oncology, 30 (11). pp. 1697-1727. ISSN 0923-7534

Jepson, M, Elliott, D, Conefrey, C et al. (104 more authors) (2018) An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. Journal of Clinical Epidemiology, 99. pp. 75-83. ISSN 0895-4356

Asselain, B, Barlow, W, Bartlett, J et al. (107 more authors) (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer : meta-analysis of individual patient data from ten randomised trials. The Lancet Oncology, 19 (1). pp. 27-39. ISSN 1470-2045

Powles, T, Lackner, MR, Oudard, S et al. (18 more authors) (2016) Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 34 (14). pp. 1660-1668. ISSN 0732-183X

Powles, T, Brown, J, Larkin, J et al. (17 more authors) (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27 (5). pp. 880-886. ISSN 0923-7534

Powles, T, Wheater, M, Din, O et al. (11 more authors) (2016) A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. European Urology, 69 (3). pp. 450-456. ISSN 0302-2838

Bridgeman, VL, Wan, E, Foo, S et al. (12 more authors) (2016) Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. Molecular Cancer Therapeutics, 15 (1). pp. 172-183. ISSN 1535-7163

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Coleman, R, Powles, T et al. (102 more authors) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet, 386 (10001). 1353 - 1361. ISSN 0140-6736

Olson, TA, Murray, MJ, Rodriguez-Galindo, C et al. (27 more authors) (2015) Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. Journal of Clinical Oncology, 33 (27). pp. 3018-3028. ISSN 0732-183X